CDK4 and venous thromboembolism: Among all trial participants, the addition of CDK4/6i significantly increases the risk of venous thromboembolism (RR = 2.65; 95% CI: 1.40–5.00; p = 0.03) (Table 4, Supplementary Figure 1a–n).